These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 27974704)

  • 1. MED15 overexpression in prostate cancer arises during androgen deprivation therapy via PI3K/mTOR signaling.
    Offermann A; Vlasic I; Syring I; Vogel W; Ruiz C; Zellweger T; Rentsch CA; Hagedorn S; Behrends J; Nowak M; Merseburger A; Bubendorf L; Kirfel J; Duensing S; Adler D; Perner S
    Oncotarget; 2017 Jan; 8(5):7964-7976. PubMed ID: 27974704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MED15, encoding a subunit of the mediator complex, is overexpressed at high frequency in castration-resistant prostate cancer.
    Adler D; Menon R; Braun M; Offermann A; Queisser A; Boehm D; Vogel W; Rüenauver K; Ruiz C; Zellweger T; Svensson M; Andren O; Kristiansen G; Wernert N; Bubendorf L; Kirfel J; Biskup S; Perner S
    Int J Cancer; 2014 Jul; 135(1):19-26. PubMed ID: 24374838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The PI3K-AKT-mTOR Pathway and Prostate Cancer: At the Crossroads of AR, MAPK, and WNT Signaling.
    Shorning BY; Dass MS; Smalley MJ; Pearson HB
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32630372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reciprocal feedback inhibition of the androgen receptor and PI3K as a novel therapy for castrate-sensitive and -resistant prostate cancer.
    Qi W; Morales C; Cooke LS; Johnson B; Somer B; Mahadevan D
    Oncotarget; 2015 Dec; 6(39):41976-87. PubMed ID: 26506516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance.
    Edlind MP; Hsieh AC
    Asian J Androl; 2014; 16(3):378-86. PubMed ID: 24759575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of PI3K-AKT-mTOR Pathway as a Pro-Survival Signaling and Resistance-Mediating Mechanism to Therapy of Prostate Cancer.
    Pungsrinont T; Kallenbach J; Baniahmad A
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer.
    Carver BS; Chapinski C; Wongvipat J; Hieronymus H; Chen Y; Chandarlapaty S; Arora VK; Le C; Koutcher J; Scher H; Scardino PT; Rosen N; Sawyers CL
    Cancer Cell; 2011 May; 19(5):575-86. PubMed ID: 21575859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. mTOR is a fine tuning molecule in CDK inhibitors-induced distinct cell death mechanisms via PI3K/AKT/mTOR signaling axis in prostate cancer cells.
    Berrak O; Arisan ED; Obakan-Yerlikaya P; Coker-Gürkan A; Palavan-Unsal N
    Apoptosis; 2016 Oct; 21(10):1158-78. PubMed ID: 27484210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complex impacts of PI3K/AKT inhibitors to androgen receptor gene expression in prostate cancer cells.
    Liu L; Dong X
    PLoS One; 2014; 9(10):e108780. PubMed ID: 25360799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brassinin induces apoptosis in PC-3 human prostate cancer cells through the suppression of PI3K/Akt/mTOR/S6K1 signaling cascades.
    Kim SM; Park JH; Kim KD; Nam D; Shim BS; Kim SH; Ahn KS; Choi SH; Ahn KS
    Phytother Res; 2014 Mar; 28(3):423-31. PubMed ID: 23686889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer.
    Bitting RL; Armstrong AJ
    Endocr Relat Cancer; 2013 Jun; 20(3):R83-99. PubMed ID: 23456430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation.
    Ghosh PM; Malik SN; Bedolla RG; Wang Y; Mikhailova M; Prihoda TJ; Troyer DA; Kreisberg JI
    Endocr Relat Cancer; 2005 Mar; 12(1):119-34. PubMed ID: 15788644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Addressing the Reciprocal Crosstalk between the AR and the PI3K/AKT/mTOR Signaling Pathways for Prostate Cancer Treatment.
    Raith F; O'Donovan DH; Lemos C; Politz O; Haendler B
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Skp2 regulates androgen receptor through ubiquitin-mediated degradation independent of Akt/mTOR pathways in prostate cancer.
    Li B; Lu W; Yang Q; Yu X; Matusik RJ; Chen Z
    Prostate; 2014 Apr; 74(4):421-32. PubMed ID: 24347472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual targeting of the androgen receptor and PI3K/AKT/mTOR pathways in prostate cancer models improves antitumor efficacy and promotes cell apoptosis.
    Sugawara T; Nevedomskaya E; Heller S; Böhme A; Lesche R; von Ahsen O; Grünewald S; Nguyen HM; Corey E; Baumgart SJ; Georgi V; Pütter V; Fernández-Montalván A; Vasta JD; Robers MB; Politz O; Mumberg D; Haendler B
    Mol Oncol; 2024 Mar; 18(3):726-742. PubMed ID: 38225213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The androgen receptor-lncRNASAT1-AKT-p15 axis mediates androgen-induced cellular senescence in prostate cancer cells.
    Mirzakhani K; Kallenbach J; Rasa SMM; Ribaudo F; Ungelenk M; Ehsani M; Gong W; Gassler N; Leeder M; Grimm MO; Neri F; Baniahmad A
    Oncogene; 2022 Feb; 41(7):943-959. PubMed ID: 34667276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MED19 alters AR occupancy and gene expression in prostate cancer cells, driving MAOA expression and growth under low androgen.
    Weber H; Ruoff R; Garabedian MJ
    PLoS Genet; 2021 Jan; 17(1):e1008540. PubMed ID: 33513133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isorhamnetin inhibited the proliferation and metastasis of androgen-independent prostate cancer cells by targeting the mitochondrion-dependent intrinsic apoptotic and PI3K/Akt/mTOR pathway.
    Cai F; Zhang Y; Li J; Huang S; Gao R
    Biosci Rep; 2020 Mar; 40(3):. PubMed ID: 32039440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cotargeting Androgen Receptor Splice Variants and mTOR Signaling Pathway for the Treatment of Castration-Resistant Prostate Cancer.
    Kato M; Banuelos CA; Imamura Y; Leung JK; Caley DP; Wang J; Mawji NR; Sadar MD
    Clin Cancer Res; 2016 Jun; 22(11):2744-54. PubMed ID: 26712685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the Vav3 oncogene enhances docetaxel-induced apoptosis through the inhibition of androgen receptor phosphorylation in LNCaP prostate cancer cells under chronic hypoxia.
    Nomura T; Yamasaki M; Hirai K; Inoue T; Sato R; Matsuura K; Moriyama M; Sato F; Mimata H
    Mol Cancer; 2013 Apr; 12():27. PubMed ID: 23566222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.